(539 days)
No
The summary does not mention AI or ML, and the device description focuses on electrical stimulation and hardware components.
Yes
The "Intended Use / Indications for Use" section explicitly states that the system is "intended to treat patients with an overactive bladder (OAB) and associated symptoms." Treating a medical condition makes it a therapeutic device.
No
The device description clearly states its purpose is to "deliver non-invasive access to the sacral nerve plexus through transcutaneous electrical stimulation of the posterior tibial nerve" to treat overactive bladder symptoms, indicating a therapeutic function rather than a diagnostic one.
No
The device description explicitly states that the ZIDA System is a combination of a battery-powered ZIDA Control Unit and a ZIDA Embedded Garment (Sock or Tights), indicating it includes hardware components.
Based on the provided information, the ZIDA Wearable Neuromodulation System is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- ZIDA System Function: The ZIDA System is a neuromodulation system that delivers electrical stimulation to the posterior tibial nerve. It is a therapeutic device used to treat a condition (overactive bladder) by directly interacting with the patient's body.
- No Sample Analysis: The description does not mention the collection or analysis of any biological samples from the patient.
Therefore, the ZIDA Wearable Neuromodulation System falls under the category of a therapeutic medical device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
ZIDA Wearable Neuromodulation System is a neuromodulation system that is intended to treat patients with an overactive bladder (OAB) and associated symptoms of urinary frequency, and urge incontinence.
Product codes
NAM
Device Description
ZIDA Wearable Neuromodulation System (ZIDA System) is a home-use system that is a neuromodulation system designed to deliver non-invasive access to the sacral nerve plexus through transcutaneous electrical stimulation of the posterior tibial nerve. The method of treatment is referred to as Transcutaneous Tibial Nerve Stimulation (TTNS).
The ZIDA System is a combination of the battery powered ZIDA Control Unit and the ZIDA Embedded Garment (Sock or Tights).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
posterior tibial nerve
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Prescription device for home use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Usability: ZIDA usability testing was conducted in a simulated home use environment. The tester had access to the basic facilities and tools to effectively operate the device including reading the instructions and user guide. Fifteen (15) participants were provided the ZIDA Control Unit, a ZIDA embedded sock, instruction manual and quick start guide. Users had no prior training or exposure to the ZIDA device. The study results support the device labeling contains appropriate information for home use.
Clinical Data: Two clinical investigations of the ZIDA Wearable Neuromodulation System were conducted in the United States at a single center.
- Initial Investigation: Enrolled 23 out of a planned 50 patient study. This study was stopped to amend the clinical protocol to obtain effectiveness information. The primary objective of the first study was to assess the Quality of Life (QoL) of subjects treated with the ZIDA device.
- Second Study: Launched after protocol amendment, enrolling 40 subjects. In total, 63 subjects were randomized 1:1 to treatment with the device or sham treatment with the device not activated. The second study sought to determine whether the ZIDA device was substantially equivalent in terms of safety and effectiveness to the Urgent PC device in treating overactive bladder (OAB) symptoms of urinary urgency, urinary frequency, and urge incontinence. Subjects were diagnosed with OAB based on meeting the criteria defined by the International Continence Society (average urinary frequency: ≥8 voids and ≥1 urgency episode (with or without incontinence) per 24 hours, normal urinalysis, and a score of 60 or higher on the Incontinence impact questionnaire-OAB-q Short Form, 4-week recall). Subjects were provided the device and instructed to have once-weekly treatments of 30 minutes with the device for 12 consecutive weeks. The ZIDA device was self-administered by the subject at home. Participants reported 100% compliance with all weekly treatments for 12 weeks on both studies. In the second study, treatment success was defined as at least a 50% reduction in urinary urgency voids with or without incontinence or at least a 30% reduction in the frequency of daytime or nighttime voids from baseline to week 12.
Key results (second study):
- The treatment success rate in the ZIDA device arm was 80%, as compared to the treatment success rate of 39% in the sham control arm. Hence, the primary endpoint of the study was considered met.
- Subjects on the ZIDA device had a greater decrease in the number of urgent episodes from baseline to Week 12 as compared to subjects on sham control.
- A greater decrease in the number of incontinence episodes from baseline to Week 12 compared to sham control.
- A greater decrease in the total number of voids per day from baseline to Week 12 compared to sham control.
- The study results from the second study based on the bladder diaries (urinary frequency, urinary urgency, and urinary incontinence) for the ZIDA device were similar to the results based on the bladder diaries reported in the studies evaluating the predicate Urgent PC device.
Adverse Events:
- Two adverse events (AEs) were reported over the course of the first study, both in the sham control arm and both considered unrelated to the device.
- Five AEs were reported over the second study: two subjects (active ZIDA device arm) reported a mild AE of urinary tract infection which was not considered related to the study treatment; and two subjects (active ZIDA device arm) reported an expected mild AE of pain in the foot during or immediately after treatment that resolved within half an hour of treatment cessation.
Quality of Life: In both the first and second studies, quality of life was improved in subjects treated with the ZIDA device compared to those in the sham control arms. In the second study, subjects in the ZIDA device arm reported greater satisfaction with the ZIDA device and improvement of OAB symptoms than subjects in the sham control arm. Subjects in the ZIDA device group were more likely to recommend the device compared to those in the sham control group.
Key Metrics
Not Found (specific metrics such as AUC, MRMC, Sensitivity, Specificity, PPV, NPV were not provided, only success rates and changes in symptom episodes).
Predicate Device(s)
Urgent PC Neuromodulation System, K071822
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5310 Nonimplanted, peripheral electrical continence device.
(a)
Identification. A nonimplanted, peripheral electrical continence device is a device that consists of an electrode that is connected by an electrical cable to a battery-powered pulse source. The electrode is placed onto or inserted into the body at a peripheral location and used to stimulate the nerves associated with pelvic floor function to maintain urinary continence. When necessary, the electrode may be removed by the user.(b)
Classification. Class II, subject to the following special controls:(1) That sale, distribution, and use of this device are restricted to prescription use in accordance with § 801.109 of this chapter.
(2) That the labeling must bear all information required for the safe and effective use of the device as outlined in § 801.109(c) of this chapter, including a detailed summary of the clinical information upon which the instructions are based.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
March 19, 2021
Exodus Innovations % Cherita James Regulatory Consultant M Squared Associates, Inc. 575 8th Avenue, Suite 1212 New York, NY 10018
K192731 Re:
Trade/Device Name: ZIDA Wearable Neuromodulation System Regulation Number: 21 CFR§ 876.5310 Regulation Name: Nonimplanted, Peripheral Electrical Continence Device Regulatory Class: II Product Code: NAM Dated: February 26, 2021 Received: March 1, 2021
Dear Cherita James:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
1
You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatoryinformation/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Jessica Nguven, Ph.D. Assistant Director DHT3B: Division of Reproductive. Gynecology and Urology Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K192731
Device Name
ZIDA Wearable Neuromodulation System
Indications for Use (Describe)
ZIDA Wearable Neuromodulation System is a neuromodulation system that is intended to treat patients with an overactive bladder (OAB) and associated symptoms of urinary frequency, and urge incontinence.
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(K) SUMMARY
The following information is provided as required by 21 CFR § 807.87 for ZIDA 510(k) premarket notification. In response to the Safe Medical Devices Act of 1990, the following is a summary of the information upon which the substantial equivalence determination is based.
| Sponsor: | Exodus |
|---|---|
| 1 Exodus Road | |
| Sufa, 85457 | |
| Israel | |
| Isaac Oppenheim | |
| Israel Office: 08-611-5525 | |
| US: 703-466-0259 |
Contact: Cherita James M Squared Associates, Inc. 127 West 30th St, 9th Floor New York, NY 10001 Ph: 347-954-0624 Fax: 703-562-9797 Email: Cjames@MSquaredAssociates.com
| Date of Submission: | March 18, 2021 |
|---|---|
| Proprietary Name: | ZIDA Wearable Neuromodulation System |
| Common Name: | non-implanted peripheral nerve stimulator for incontinence |
| Regulatory Class: | II |
| Regulation: | 876.5310 Nonimplanted, peripheral electrical continence device. |
| Product Codes: | NAM |
| Predicate Device: | Urgent PC Neuromodulation System, K071822, NAM |
Device Description: ZIDA Wearable Neuromodulation System (ZIDA System) is a home-use system that is a neuromodulation system designed to deliver non-invasive access to the sacral nerve plexus through transcutaneous electrical stimulation of the posterior tibial nerve. The method of treatment is referred to as Transcutaneous Tibial Nerve Stimulation (TTNS).
The ZIDA System is a combination of the battery powered ZIDA Control Unit and the ZIDA Embedded Garment (Sock or Tights).
4
Indications for Use: ZIDA Wearable Neuromodulation System is a neuromodulation system that is intended to treat patients with an overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.
Substantial Equivalence Rationale
The claim of substantial equivalence of the ZIDA Wearable Neuromodulation System) to the product identified above is based on the comparison of the indications for use, intended use, principles of operation, mechanism of action, and performance characteristics.
Indications and Intended Use
Both the ZIDA System and the Urgent PC have similar intended use: to treat patients with Overactive Bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence by weekly 30- minute stimulation of the nerve fiber at the posterior tibial nerve.
| | ZIDA System
Subject device | URGENT PC UPC 200-A |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| K# | TBD | K071822 |
| Product Code | NAM | NAM |
| Indication for Use | ZIDA Wearable Neuromodulation
System is a neuromodulation
system that is intended to treat
patients with an overactive bladder
(OAB) and associated symptoms of
urinary urgency, urinary frequency,
and urge incontinence. | The Urgent PC Neuromodulation
System is intended to treat patients
with an overactive bladder (OAB)
and associated symptoms of urinary
urgency, urinary frequency, and
urge incontinence. |
| Target population | OAB patients/male and female | OAB patients/male and female |
| Intended use | Nerve stimulation through
transcutaneous electrical
stimulation of the posterior tibial
nerve (TTNS) near the ankle | Nerve stimulation through
percutaneous electrical stimulation
of the posterior tibial nerve (PTNS)
near the ankle |
| Intended user | Prescription device for home use | Prescription device for physician
use in office |
| Treatment duration | Twelve 30 minute tx once per
week. If symptoms reappear, revert
to last previously effective tx
schedule | Twelve 30 minute tx once per
week. If symptoms reappear, revert
to last previously effective tx
schedule |
Control Unit Characteristics
The Control Unit differences between the subject and predicate device are minimal.
5
| | | URGENT PC
UPC 200-A |
|---------------------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------|
| Description | ZIDA | |
| K# | TBD | K071822 |
| Power Source(s) | 1 x AAA battery | 9V battery |
| Number of Output Modes | 2
Test Mode
Therapy mode | 2
Test Mode
Therapy mode |
| Timer Range (minutes) | Yes, treatment shuts
down after 30 minutes
countdown | Yes, treatment
mode shuts down
after 30 minutes
countdown |
| Compliance with Voluntary Standards? | IEC 60601-1,
IEC 60601-1-2
IEC 60601-1-11
IEC 60601-2-10 | IEC 60601-1,
IEC 60601-1-2
IEC 60601-2-10, |
| Compliance with 21 CFR 898? | N/A- no lead wires,
control unit snaps to
garment electrode | Unknown |
| Weight (g) | 26g | unknown |
| Dimensions (mm) (W x H x D) | 65mm X 40mm X
17mm | 150mm X 75mm X
50mm |
| Housing Materials and
Construction | ABS/PC | ABS/PC |
Device Outputs
While the maximum outputs of the ZIDA Control Unit are greater than those of the Urgent PC, they are within the normal outputs of the TENS devices commonly prescribed for pain. As the mechanism of action is Posterior Tibial Nerve Stimulation, and the subject device utilizes skin contacting electrodes, the required output is higher than for the predicate device that has a percutaneous needle electrode. The outputs of the ZIDA Control Unit does not present new issues of safety or effectiveness.
| Description | ZIDA | URGENT PC UPC
200-A | Substantial Equivalence |
|-------------|-----------------------------------------------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| K# | TBD | K071822 | -- |
| Waveform | Monophasic
square wave | Monophasic square
wave | Same waveform |
| Shape | rectangular | rectangular | Same shape |
| Current | Adjustable
from 0-156
mA (9.9mA
RMS) | Adjustable from 0-
19mA | The method of delivery of the ZIDA is a
skin contact garment electrode, while the
Urgent PC is a needle electrode.
Differences in maximum current do not
impact the safety and effectiveness due to |
6
| Description | ZIDA | URGENT PC UPC
200-A | Substantial Equivalence |
|-------------|------|------------------------|----------------------------------------------|
| K# | TBD | K071822 | -- |
| | | | the differing technological characteristics. |
Garment Electrode
There are significant differences in the Urgent PC predicate needle electrode and the ZIDA Garment Electrode due to the different electrical current delivery to the ZIDA electrode presents less potential for adverse events (infection, pain during insertion, improper positioning) than the needle electrode. Garment electrodes are effectively used for nerve stimulation with traditional TENS stimulators for pain; the differences in the ZIDA electrode when compared to the Urgent PC needle electrode do not present new issues of safety or effectiveness.
Both the subject and EMSI garment device support the same scientific methodology and are intended as single patient reusable garment electrodes to deliver electrical stimulation. The ZIDA garment is intended for use only with the ZIDA stimulator, while the EMSI device may be used with multiple devices. This difference does not present any new concerns for safety and effectiveness.
| Description | ZIDA | URGENT PC UPC 200-A | EMSI Garment Electrode |
|---|---|---|---|
| K# | TBD | K071822 | K090889 |
| Product Code | NAM | NAM | GXY Cutaneous electrode |
| Indication for Use and | |||
| Intended Use | Embedded conductive garment electrode is interface between ZIDA stimulator (Control Unit) and patient skin for delivery of electrical stimulation | The Urgent PC Lead Set transfers electrical current from the stimulator via a Needle electrode | Electrodes intended for use as reusable (single patient) cutaneous, flexible, conductive garment/fabric electrodes for interface between electrical stimulators such as IF, galvanic, TENS, etc. and patient skin for delivery of electrical stimulation. |
| Description | The yarn of the conductive surface of the garment is 80% Nylon/20% Silver as a percentage by weight. The purity of silver used is 99.9% metallic silver with 100% electrode surface area coverage. The dimension of the | The EMSI Garment Electrodes are a cloth type device weft knitted of a continuous fiber made up of 77% Nylon and 23% Silver. Each device is flexible and is available in a range of sizes to ensure good patient contact. A male snap connector is placed |
7
| Description | ZIDA | URGENT PC UPC
200-A | EMSI Garment
Electrode |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | top electrode and bottom
conductive surface is
2cm X 4cm X 0.59cm.
The wire connection is a
sublimated transfer print
that runs from ankle to
the arch of heel. | | (Reference Device)
within the fabric weave
and is connected via the
female snap connector
to a short lead wire. |
| | The non-conductive
portions of the garment
are made up of
wool/cotton/nylon blend
and double cover Lycra
elastomer. | | The lead wire has a
female pin connection at
the distal end which
accepts the lead wire
connection from the
stimulator. The entire
fabric is made up of
conductive material to
provide uniform current
distribution when
connected to a
stimulator. |
| Connection type | Male and female snaps | Lead wire set | Snap and lead wire |
| Sizes | S, M, L, extra-L sock or
tight | N/A | Multiple configurations
and sizes based on
intended area of use |
| Reusable | Single patient | N/A Sterile single use | Single patient |
| Washing validation | 30 washes | N/A | 30 washes |
| Patient contact | Intact skin | Percutaneous insertion | Intact skin |
| Biocompatibility | ISO 10993-5 and - 10 | Unknown | ISO 10993-5 and - 10 |
Performance testing
The ZIDA System has been tested and conforms to the following applicable standards:
| Standard |
|---|
| ANSI AAMI 60601-1 Medical electrical equipment - Part 1: General requirements for basic safety and essential |
| performance. |
| IEC 60601-1-11: General requirements for basic safety and essential performance - Collateral Standard: |
| Requirements for medical electrical equipment and medical electrical systems used in the home healthcare |
| environment |
| ANSI AAMI IEC 60601-1-2 General requirements for basic safety and essential performance -- Collateral |
| Standard: Electromagnetic disturbances -- Requirements and tests |
| IEC 60601-2-10: Particular requirements for the basic safety and essential performance of nerve and muscle |
| stimulators |
| IEC 60601-1-6 Edition 3.1 2013-10 Medical electrical equipment - Part 1-6: General requirements for basic |
| safety and essential performance - Collateral standard: Usability |
| ISO 10993-1 Evaluation and testing within a risk management process |
| ISO 10993-5 Tests for in vitro cytotoxicity |
| ISO 10993-10 Tests for irritation and skin sensitization |
| ISO 14971 Medical devices -- Application of risk management to medical devices |
| ISO 13485 Medical devices – Quality management systems – Requirements for regulatory purposes |
| ASTM E3162-18 Standard Practice Measuring the Durability of Antibacterial Agents Applied to Textiles under |
| Simulated Home Laundering Conditions |
| IEC 62366-1:2015 Medical Devices-Part 1: Application of usability engineering to medical devices |
8
Usability
ZIDA usability testing was conducted in a simulated home use environment. The tester had access to the basic facilities and tools to effectively operate the device including reading the instructions and user guide. Fifteen (15) participants were provided the ZIDA Control Unit, a ZIDA embedded sock, instruction manual and quick start guide. Users had no prior training or exposure to the ZIDA device. The study results support the device labeling contains appropriate information for home use.
Clinical Data
Two clinical investigations of the ZIDA Wearable Neuromodulation System were conducted in the United States at a single center to obtain clinical information to demonstrate whether the device is substantially equivalent to the predicate device, the Urgent PC Neuromodulation System. The initial investigation enrolled 23 out of a planned 50 patient study but was stopped to amend the clinical protocol to obtain effectiveness information. After the protocol was amended, the second trial was launched enrolling 40 subjects. In total, 63 subjects, were randomized 1:1 to treatment with the device or shamtreatment with the device not activated.
The primary objective of the first study was to assess the Quality of Life (QoL) of subjects treated with the ZIDA device. The second study sought to determine whether the ZIDA device was substantially equivalent in terms of safety and effectiveness to the Urgent PC device in treating overactive bladder (OAB) symptoms of urinary urgency, urinary frequency, and urge incontinence. Subjects were diagnosed with OAB based on meeting the criteria defined by the International Continence Society, i.e., subjects with an average urinary frequency: ≥8 voids and ≥1 urgency episode (with or without incontinence) per 24 hours and who had a normal urinalysis and a score of 60 or higher on the Incontinence impact questionnaire-OAB-q Short Form, 4-week recall were considered eligible for the study. Subjects were provided the device and instructed to have once-weekly treatments of 30 minutes with the device for 12 consecutive weeks. The ZIDA device was self-administered by the subject at home. Participants reported 100% compliance with all weekly treatments for 12 weeks on both studies. In the second study, treatment success was defined as at least a 50% reduction in urinary urgency voids with or without incontinence or at least a 30% reduction in the frequency of daytime or nighttime voids from baseline to week 12. The treatment success rate in the ZIDA device arm was 80%, as compared to the treatment success rate of 39% in the sham control arm. Hence, the primary endpoint of the study was considered met. Subjects on the ZIDA device had a greater decrease in the number of urgent episodes from baseline to Week 12 as compared to subjects on sham control; a greater decrease in the number of incontinence episodes from baseline to Week 12 compared to sham control, and a greater decrease in the total number of voids per day from baseline to Week 12 compared to sham control. The study results from the second study based on the bladder diaries (urinary frequency, urinary urgency, and urinary incontinence) for the ZIDA device were similar to the results based on the bladder diaries reported in the studies evaluating the predicate Urgent PC device.
Two adverse events (AEs) were reported over the course of the first study, both in the sham control arm and both considered unrelated to the device. Five AEs were reported over the second study: two subjects, both in the active ZIDA device arm, reported a mild AE of urinary tract infection which was not considered related to the study treatment; and two subjects, also both in the active ZIDA device arm,
9
reported an expected mild AE of pain in the foot during or immediately after treatment that resolved within half an hour of treatment cessation.
In both the first and second studies, quality of life was improved in subjects treated with the ZIDA device compared to those in the sham control arms. In the second study, subjects in the ZIDA device arm reported greater satisfaction with the ZIDA device and improvement of OAB symptoms than subjects in the sham control arm. Subjects in the ZIDA device group were more likely to recommend the device compared to those in the sham control group.
In summary, the clinical information obtained in the 2 studies indicates that the ZIDA device is substantially equivalent, in improving symptoms of urinary incontinence, urinary urgency, and total urinary frequency well as improving quality of life for subjects with overactive bladder, to the predicate device Urgent PC Neuromodulation System.
Conclusion
There are no differences between the subject device and the predicate with respect to indications and intended use. Technological differences in the predicates and subject devices do not present new issues of safety and effectiveness. Exodus has evaluated the benefit-risk profile of the ZIDA System in comparison to the predicate device in accordance with FDA's Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics, September 2018, as well as the risk and Special Controls identified in the Reclassification Order for K992069. The clinical trials and risk evaluation assessed the benefits and risk associated with the ZIDA (transcutaneous tibial nerve stimulator-TTNS) when compared to the Urgent PC (K071822), percutaneous tibial nerve stimulator- PTNS) in treating patients with Overactive Bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence by neuromodulation of the sacral nerve. The ZIDA TTNS has the same intended use as the predicate Urgent PC PTNS, and different technological characteristics which do not raise different questions of safety and effectiveness.
Beyond the general indications for use of the EMSI Garment Electrode (reference device), and the OAB specific indication of the ZIDA sock or tight, and lead wire to snap vs direct snap connection, the garment electrodes are utilized in the same method and testing has confirmed comparable performance. There is no difference in the ZIDA Garment Electrode and the EMSI Garment Electrode that present new issues of safety and effectiveness.
The ZIDA Wearable Neuromodulation System is substantially equivalent to the Urgent PC Neuromodulation System, K071822.